With talquetamab-based combinations (Tal-DP and Tal-D) now showing efficacy at first relapse, if approved, how will you position GPRC5D-targeted bispecifics relative to BCMA-directed therapy in your treatment algorithm for relapsed/refractory MM after 1 prior line of therapy?